

**ANTICIPATED ACQUISITION BY ROCHE DIAGNOSTICS  
LIMITED OF CERTAIN ASSETS HELD BY LUMIRADX  
GROUP LIMITED (IN ADMINISTRATION) AND  
LUMIRADX INTERNATIONAL LIMITED (IN  
ADMINISTRATION)**

23 May 2024

**NOTICE UNDER SECTION 96(2A) OF THE ENTERPRISE ACT 2002  
PUBLISHED PURSUANT TO SECTION 107(1)(I) OF THE ENTERPRISE  
ACT 2002**

The Competition and Markets Authority (**CMA**) hereby gives notice pursuant to section 96(2A) of the Enterprise Act 2002 (the **Act**) that the merger notice provided by (i) Roche Diagnostics Limited (**Roche**) and (ii) LumiraDx Group Limited (in administration) and LumiraDx International Limited (in administration) (**LumiraDx**) in relation to Roche's acquisition of certain assets of LumiraDx (the **Transaction**) meets the requirements of section 96(2) of the Act.

The initial period defined in section 34ZA(3) of the Act in relation to the Transaction will therefore commence on the first working day after the date of this notice, ie on 24 May 2024. The deadline for the CMA to announce its decision whether to refer the Merger for a phase 2 investigation is therefore 19 July 2024.